SCHEMBL4130746

SCHEMBL4130746

CC1CCCCN1C(=O)c1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.60
HPGD P15428 2/20 0.60
L3MBTL3 Q96JM7 5/20 0.50
L3MBTL1 Q9Y468 5/20 0.50
MBTD1 Q05BQ5 2/20 0.50
TP53BP1 Q12888 2/20 0.50
L3MBTL4 Q8NA19 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
LMNA P02545 1/20 0.48
HRH3 Q9Y5N1 3/20 0.47
ALDH1A1 P00352 2/20 0.47
NAMPT P43490 1/20 0.43
GRM5 P41594 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130761 0.86 L3MBTL3 (0.47) GAAHPGDL3MBTL3L3MBTL1MBTD1
SCHEMBL4935030 0.84 HRH3 (0.47) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4125834 0.84 HPGD (0.51) GAAHPGDL3MBTL3L3MBTL1CA12
SCHEMBL4147049 0.83 L3MBTL3 (0.67) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4139958 0.82 L3MBTL3 (0.66) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4130681 0.82 L3MBTL3 (0.66) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4136891 0.82 L3MBTL3 (0.62) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4137004 0.81 ADRA1A (0.53) GAAHPGDHRH3GRM5
SCHEMBL4136511 0.81 KMT2A (0.62) HPGDL3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4937015 0.81 GAA (0.46) GAAHPGDCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 GAA 1882/4885HPGD 496/4885L3MBTL3 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.